Jennison Associates
LKFT

Jennison Associates’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Jennison Associates’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-302,250
Closed -$16.9M – 628
2022
Q2 		$16.9M Buy
+302,250
New +$17.9M 0.02% 329

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jennison Associates's LKFT Position: Q3 2022 in Review

Jennison Associates sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2022, closing a stake of 302,250 shares — an estimated $16.9M sold.

Jennison Associates first reported a position in LKFT in Q2 2022 and held it in 1 quarter. The position peaked at $16.9M in Q2 2022. 83 funds tracked by Wall St. Rank hold LKFT as of Q3 2022.

  • Jennison Associates reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2022 after selling out during the quarter.
  • Jennison Associates sold 302,250 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2022, an estimated $16.9M.
  • Jennison Associates first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2022 and held it in 1 quarter.
  • Jennison Associates's Lakefront Biotherapeutics American Depositary Shares position peaked at $16.9M in Q2 2022.
  • 83 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2022.

Based on Jennison Associates's 13F filing for Q3 2022, filed 1 Nov 2022.